0001610618-24-000093.txt : 20240719
0001610618-24-000093.hdr.sgml : 20240719
20240719163859
ACCESSION NUMBER: 0001610618-24-000093
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240718
FILED AS OF DATE: 20240719
DATE AS OF CHANGE: 20240719
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tadvalkar Laura
CENTRAL INDEX KEY: 0002020464
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36912
FILM NUMBER: 241128192
MAIL ADDRESS:
STREET 1: CIDARA THERAPEUTICS, INC.
STREET 2: 6310 NANCY RIDGE DRIVE, SUITE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cidara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001610618
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461537286
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6310 NANCY RIDGE DRIVE
STREET 2: SUITE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-752-6170
MAIL ADDRESS:
STREET 1: 6310 NANCY RIDGE DRIVE
STREET 2: SUITE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: K2 THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20140611
4
1
wk-form4_1721421532.xml
FORM 4
X0508
4
2024-07-18
0
0001610618
Cidara Therapeutics, Inc.
CDTX
0002020464
Tadvalkar Laura
6310 NANCY RIDGE DRIVE
STE 101
SAN DIEGO
CA
92121
1
0
0
0
0
Stock Option (right to buy)
12.64
2024-07-18
4
A
0
2125
0
A
2034-07-17
Common Stock
2125
2125
D
The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2025 annual meeting of stockholders.
Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
/s/ Shane Ward, Attorney-in-Fact
2024-07-19